PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 – 2014)
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Protein tyrosine phosphatase 1B (PTP1B) plays an important role in the negative regulation of insulin signal transduction pathway and has emerged as novel therapeutic strategy for the treatment of type 2 diabetes. PTP1B inhibitors enhance the sensibility of insulin receptor (IR) and have favorable curing effect for insulin resistance-related diseases. A large number of PTP1B inhibitors, either synthetic or isolated as bioactive agents from natural products, have developed and investigated for their ability to stimulate insulin signaling. AREAS COVERED: This review includes an updated summary (2011 - 2014) of PTP1B inhibitors that have been published in patent applications, with an emphasis on their chemical structure, mode of action and therapeutic outcomes. The usefulness of PTP1B inhibitors as pharmaceutical agents for the treatment of type 2 diabetes is also discussed. EXPERT OPINION: PTP1B inhibitors show beneficial effects to enhance sensibility of IR by restricting the activity of enzyme and have favorable curing effects. However, structural homologies in the catalytic domain of PTP1B with other protein tyrosine phosphatases (PTPs) like leukocyte common antigen-related, CD45, SHP-2 and T-cell-PTP present a challenging task of achieving selectivity. Thus, for therapeutic application of PTP1B inhibitors, highly selective molecules exhibiting desired effects without side effects are expected to find clinical application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 2×
“These include isothiazolinones [55-57], 1,2-nephtha quinines [58,59], formylchromones [60,61], Cyclopenta[d] [1,2]-oxazine [62], paracaseolide A analogs [63], Phenylpropanoic acid-based phosphotyrosine mimetics [64], Diphenylether derivative [65], pyridazine analogs, acetophenones, catechols and many more groups that…”
BackgroundCritical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
Protein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
Dresner, A., Laurent, D., Marcucci, M., Griffin, M. E., Dufour, S., Cline, G. W., Slezak, L. A., Andersen, D. K., Hundal, R. S., Rothman, D. L., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5001 · Cited by 1,311
Klaman, L. D., Boss, O., Peroni, O. D., Kim, J. K., Martino, J. L., Zabolotny, J. M., Moghal, N., Lubkin, M., Kim, Y.-B., Sharpe, A. H., et al. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.15.5479-5489.2000 · Cited by 1,235 · cited 1×
“This is likely to be associated with increased energy expenditure owing to enhanced leptin sensitivity [36].”
BackgroundInsulin sensitivity: Modulation by nutrients and inflammation
Schenk, S., Saberi, M., & Olefsky, J. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34260 · Cited by 1,191 · cited 2×
“With respect to nutrient metabolism, insulin mainly targets muscle, liver and adipose tissue, and the responses of these targets to insulin and other hormones determine circulating concentrations of glucose, fatty acids and other metabolites [10,11].”
BackgroundReversible oxidation and inactivation of protein tyrosine phosphatases in vivo
Meng, T.-C., Fukada, T., & Tonks, N. K. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00445-8 · Cited by 1,040
Etiology of Insulin Resistance
Petersen, K. F., & Shulman, G. I. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.009 · Cited by 825 · cited 1×
“Insulin resistance is a major pathophysiological factor in the development of type 2 diabetes, defined as a diminished ability of cells, such as myocytes, adipocytes and hepatocytes, to respond to the action of insulin [3].”
BackgroundNeuronal PTP1B regulates body weight, adiposity and leptin action
Bence, K. K., Delibegovic, M., Xue, B., Gorgun, C. Z., Hotamisligil, G. S., Neel, B. G., & Kahn, B. B. (2006) · Nature Medicine · doi:10.1038/nm1435 · Cited by 633 · cited 1×
“Neuronal PTP1Bdeficient mice have reduced weight, adiposity, increased activity and energy expenditure [37].”
BackgroundMolecular characterization of a protein-tyrosine-phosphatase enriched in striatum.
Lombroso, P. J., Murdoch, G., & Lerner, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.16.7242 · Cited by 188
Cited by
Update on GLUT4 Vesicle Traffic: A Cornerstone of Insulin Action
Jaldin-Fincati, J. R., Pavarotti, M., Frendo-Cumbo, S., Bilan, P. J., & Klip, A. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.05.002 · Cited by 275
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“Inhibitors designed to bind to the active site of PTP1B often exhibit off-target binding effects to other PTPs and therefore, it would be difficult to inhibit PTP1B alone if assessed in human populations (Tamrakar et al., 2014).”
Latest approaches for the treatment of obesity
Jackson, V. M., Breen, D. M., Fortin, J.-P., Liou, A., Kuzmiski, J. B., Loomis, A. K., Rives, M.-L., Shah, B., & Carpino, P. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1044966 · Cited by 132
“Several small PTP1B inhibitors have been identified and tested pre-clinically; however the only modulator of the PTP1B pathway in clinical trials is an antisense drug called ISIS-PTP1B RX , which was shown to decrease body weight and lower HbA1c in T2D subjects [60-62] .”
Targeting breast cancer and their stem cell population through AMPK activation: novel insights
Uprety, B., & Abrahamse, H. (2022) · Cells · doi:10.3390/cells11030576 · Cited by 33
Metadata
- Authors
- Tamrakar, A. K., Maurya, C. K., & Rai, A. K.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2014-08-14
- Volume
- 24
- Issue
- 10
- Pages
- 1101-1115
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2095581714
- Cited by
- 126
- References
- 10
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 – 2014). https://app.cochat.ai/papers/10.1517/13543776.2014.947268
- The paper
- Tamrakar, A. K., Maurya, C. K., & Rai, A. K. (2014). PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 – 2014). Expert Opinion on Therapeutic Patents. https://doi.org/10.1517/13543776.2014.947268
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.